1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Mental Health Market Trends
  5. > Recent Developments in the CNS Drug Market

Recent Developments in the CNS Drug Market

  • October 2013
  • -
  • Espicom Business Intelligence
  • -
  • 76 pages

This report reviews the global market for CNS prescription drugs and recent developments within the marketplace, including collaborative agreements, recent clinical trial results and new product approvals across 8 key therapy areas.

Despite recent technological advances, relatively few novel treatments have been launched within the CNS market over the last decade. Many of the current market leaders are beginning to face generic competition or will do within the next five years.

However, the overall neuroscience market is worth approximately US$145.3 billion, and with the CNS market forming a large part of that, there is room for investment to be made. Significant unmet need remains for a number of CNS conditions and the pipeline of drug development remains strong.

This new report from Espicom reviews the recent developments in drug therapy for a number of CNS disorders, providing five-year sales for the current market leaders and forecasts for these and potential therapies to 2020, where available.

Key market questions answered by the report:

Who are the current leading players in the CNS drugs market?
What are the current treatment options for schizophrenia and bipolar disorder?
What are the recent FDA approvals for depression drugs?
Which new therapies will increase the value of the multiple sclerosis market?

The Recent Developments in the CNS Drugs Market report is the foolproof business resource for any industry executive that needs to fully understand the current and forecasted CNS market. The need for hard facts and statistics to back up everyday business decisions is essential and it is this report that can provide you with the answers.

What this report contains:

Executive Summary
The CNS Drugs market overview including the 13 current leading players

CNS market sectors breakdown including current treatment options, sales and forecast figures and what’s in the pipeline for the following therapy areas:

- Pain
- Schizophrenia and Bipolar Disorder
- Depression
- Attention Deficit Hyperactivity Disorder (ADHD)
- Epilepsy
- Multiple Sclerosis
- Alzheimer’s Disease
- Parkinson’s Disease

Table Of Contents

Recent Developments in the CNS Drug Market
Foreword 1
Executive Summary 3
The CNS Drugs Market 4
Market Overview 4
The Leading Players 6
AstraZeneca 8
Biogen Idec 8
Eli Lilly 8
Endo Pharmaceuticals 8
Forest Laboratories 9
GlaxoSmithKline 9
Johnson and Johnson 9
Lundbeck 10
Otsuka 10
Pfizer 10
Purdue Pharma/Mundipharma/Napp Pharmaceuticals 11
Shire 11
Teva 11
CNS Market Sectors 12
Pain 12
Types of Pain 12
Nociceptive Pain 12
Neuropathic Pain 12
Psychogenic Pain 13
Current Treatment Options for Pain 13
Pain Drug Sales and Forecasts 15
Neuropathic Pain Management 17
The World Health Organization's Pain Ladder 18
The Pain Pipeline 18
Pipeline Highlights and Recent Developments 21
Levadex (dihydroergotamine) 21
MoxDuo IR (morphine+oxycodone; Q8003) 22
MNK-795 (oxycodone+acetaminophen) 22
Posidur (SABER-Bupivacaine) 23
Remoxy (oxycodone) 23
Zohydro ER (hydrocodone bitartrate) 24
Schizophrenia and Bipolar Disorder 25
Current Treatment Options for Schizophrenia and Bipolar Disorder 25
Schizophrenia Drug Sales and Forecasts 26
The Schizophrenia and Bipolar Disorder Pipeline 28
Pipeline Highlights and Recent Developments 29
Aripiprazole 29
Cariprazine 29
Fanapt/Fanaptum (iloperidone) 30
Depression 31
Current Treatment Options for Depression 31
Depression Drug Sales and Forecasts 32
Recent FDA Approvals for Depression 34
Fetzima (levominacipram) 34
Brintellix (vortioxentine) 35
The Depression Pipeline 37
Pipeline Highlights and Recent Developments 38
Teva Scraps Nuvigil Development for Depression 38
BMS Terminates Development of BMS-820836 for Treatment-resistant Depression 38
Attention Deficit Hyperactivity Disorder (ADHD) 39
Current Treatment Options for ADHD 39
ADHD Drug Sales and Forecasts 40
The ADHD Pipeline 43
Pipeline Highlights and Recent Developments 43
Edivoxetine (LY2216684) 43
Metadoxine ER (MG01CI) 44
EB-1020 SR Phase IIa Pilot Study Initiated 44
Highland Raises Funds to Conduct Studies with Lead Compounds 45
Durect and Orient Select Lead Formulation for Oradur-ADHD Programme 45
Epilepsy 47
Current Treatments for Epilepsy 48
Epilepsy Drug Sales and Forecasts 49
The Epilepsy Pipeline 50
Pipeline Highlights and Recent Developments 51
Zebinix (eslicarbazepine) 51
Banzel/Inovelon (rufinamide) 52
Brivaracetam 52
Multiple Sclerosis 54
Relapsing Forms of Multiple Sclerosis 54
Primary and Secondary Progressive Multiple Sclerosis 54
Current Treatments for MS 55
Drug Sales and Forecasts 55
The MS Pipeline 59
Pipeline Highlights and Recent Developments 60
Plegridy (peginterferon beta-1a) 60
Relonsiv (interferon beta-1b) 60
S1P Receptor Agonists 61
Arbaclofen 61
Sativex for MS Spasticity 62
NEU2 Project in Support of Diagnostic for MS 62
Alzheimer's Disease 63
Current Treatments for AD 63
Alzheimer's Disease Drug Sales and Forecasts 63
The AD Pipeline 65
Pipeline Highlights and Recent Developments 68
Diagnosing AD with PET imaging 68
Lundbeck and Otsuka development agreement for Lu AE58054 68
Fixed-dose combination of memantine ER and donepezil (MDX-8704/ADS-8704) 69
Solanezumab 70
Gammagard (immunoglobulin) 70
Masitinib 71
BACE inhibitors 72
NNR modulators 73
Parkinson's Disease 74
Current Treatments for PD 74
Parkinson's Disease Drug Sales and Forecasts 75
The PD Pipeline 76
Pipeline Highlights and Recent Developments 77
Dopamine Precursor + DOPA Decarboxylase Inhibitor Combinations 77
Adenosine 2A Receptor Inhibition 77
Safinamide 78
Sources 80



List of Tables

Pain Therapies by Expected US Patent Expiry 13
Sales of Leading Pain Management Brands, 2008-2012 (US$ million) 16
Sales Forecast for Leading Pain Management Brands, 2014-2020 (US$ million) 17
Pain Clinical Pipeline 18
Schizophrenia and Bipolar Disorder Therapies by Excepted US Patent Expiry 25
Leading Schizophrenia and Bipolar Disorder Therapies by Sales, 2008-2012 (US$ million) 26
Sales Forecast for Leading Schizophrenia and Bipolar Disorder Brands, 2014-2020 (US$ million) 27
Schizophrenia and Bipolar Disorder Clinical Pipeline 28
Depression Therapies by US Patent Expiry 31
Leading Anti-depressant Brands by Sales, 2008-2012 (US$ million) 33
Sales Forecast for Leading Anti-Depressant Brands, 2014-2020 (US$ million) 33
Depression Clinical Pipeline 37
ADHD Therapies by US Patent Expiry 40
Leading ADHD Brands by Sales, 2008-2012 (US$ million) 41
Sales Forecast for Leading ADHD Brands, 2014-2020 (US$ million) 42
ADHD Clinical Pipeline 43
AEDs by Expected US Patent Expiry 48
Leading AEDs by Sales, 2008-2012 (US$ million) 49
Sales Forecast for Leading AEDs, 2014-2020 50
Epilepsy Clinical Pipeline 51
Approved Multiple Sclerosis Therapies 55
Multiple Sclerosis Leading Brands by Sales, 2008-2012 (US$ million) 57
Multiple Sclerosis Sales Forecast, 2014-2020 (US$ million) 58
Multiple Sclerosis Clinical Pipeline 59
Approved Alzheimer's Disease Therapies 63
Alzheimer's Disease Leading Brands by Sales, 2008-2012 (US$ million) 64
Alzheimer's Disease Sales Forecast for Leading Brands, 2014-2020 (US$ million) 65
Alzheimer's Disease Clinical Pipeline 67
Approved Parkinson's Disease Therapies 74
Parkinson's Disease Leading Brands by Sales, 2008-2012 (US$ million) 75
Parkinson's Disease Sales Forecast for Leading Brands, 2014-2020 (US$ million) 75
Parkinson's Disease Clinical Pipeline 76



List of Figures

CNS Market Value by Sector, 2008 (%) 5
CNS Market Value by Sector, 2012 (%) 6
Leading Companies by Reported CNS Drug Sales, 2012 (%) 7
Leading Companies by Forecast CNS Drug Sales, 2017 (%) 7
Sales Forecast for Top Five Anti-Depressant Brands, 2014-2020 (US$ million) 34
Sales Forecast for Selected ADHD Drugs, 2014-2020 (US$ million) 42
Epilepsy Drug Sales Forecast by Company, 2014-2020 (US$ million) 50
MS Drug Sales Forecast by Company, 2014-2020 (US$ million) 58
Alzheimer's Disease Forecast by Brand, 2014-2020 (US$ million) 65
Parkinson's Disease Forecast by Brand, 2014-2020 (US$ million) 76

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

  • $ 10995
  • Industry report
  • September 2016
  • by Global Data

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024 Summary Attention deficit hyperactivity disorder (ADHD) is characterized by excessive levels ...

Substance Abuse Treatment Market: By Addiction Substances (Alcohol, Drugs, Cigarettes and Coffee); By Category (Alcohol, Nicotine Dependence Therapeutics, Drug Abuse Therapeutics) & By Region -Forecast (2016-2021)

Substance Abuse Treatment Market: By Addiction Substances (Alcohol, Drugs, Cigarettes and Coffee); By Category (Alcohol, Nicotine Dependence Therapeutics, Drug Abuse Therapeutics) & By Region -Forecast (2016-2021)

  • $ 5250
  • Industry report
  • September 2016
  • by Industry ARC

Alcoholism and drug dependence and addiction, known as substance use disorders and rehabilitation treatments are classified as substance abuse treatment. Some of the common symptoms of drug abuse are ...

Psychotherapeutic Drugs Market: By Type (Antipsychotics, Antidepressants, Antimaniacs, and Anxiety Drugs) & By Geography -Forecast (2016-2021)

Psychotherapeutic Drugs Market: By Type (Antipsychotics, Antidepressants, Antimaniacs, and Anxiety Drugs) & By Geography -Forecast (2016-2021)

  • $ 5250
  • Industry report
  • August 2016
  • by Industry ARC

Psychotherapeutic drugs are used to treat mental illnesses such as extreme mood swings, social withdrawal, long lasting depression, confused thinking, and suicidal thought. schizophrenia, bipolar disorder, ...


ref:plp2013

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.